Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 749

1.

Efficacy and safety of Alemtuzumab in treatment-naive patients with relapsing-remitting multiple sclerosis: Four-year follow-up of the Care-MS I study.

Montalban X, Inshasi JS, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Palmer J, Oyuela P.

Mult Scler Relat Disord. 2014 Nov;3(6):761-2. doi: 10.1016/j.msard.2014.09.207. Epub 2014 Nov 21.

PMID:
25891612
2.

Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study.

Kieseier BC, Sahraian MA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Palmer J, Oyuela P.

Mult Scler Relat Disord. 2014 Nov;3(6):756. doi: 10.1016/j.msard.2014.09.194. Epub 2014 Nov 21.

PMID:
25891599
3.

Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.

Stuve O, Hartung HP, Freedman M, Li D, Hemmer B, Kappos L, Rieckmann P, Montalban X, Ziemssen T, Selmaj K.

Mult Scler Relat Disord. 2014 Nov;3(6):754-5. doi: 10.1016/j.msard.2014.09.190. Epub 2014 Nov 21.

PMID:
25891595
4.

Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS).

Khatri BO, Pelletier J, Kappos L, Hartung HP, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Cohen JA; TRANSFORMS Study Group.

Mult Scler Relat Disord. 2014 May;3(3):355-63. doi: 10.1016/j.msard.2013.11.006. Epub 2013 Dec 12.

PMID:
25876473
5.

Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O.

Expert Rev Neurother. 2015 Apr;15(4):339-46. doi: 10.1586/14737175.2015.1025755.

PMID:
25800129
6.

Gaps between aims and achievements in therapeutic modification of neuronal damage ("neuroprotection").

Wiendl H, Elger C, Förstl H, Hartung HP, Oertel W, Reichmann H, Schwab S.

Neurotherapeutics. 2015 Apr;12(2):449-54. doi: 10.1007/s13311-015-0348-8.

7.

Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse.

Chin RL, Deng C, Bril V, Hartung HP, Merkies IS, Donofrio PD, van Doorn PA, Dalakas MC, Latov N.

Muscle Nerve. 2015 Feb 27. doi: 10.1002/mus.24624. [Epub ahead of print]

PMID:
25728021
8.

Redox-regulated fate of neural stem progenitor cells.

Prozorovski T, Schneider R, Berndt C, Hartung HP, Aktas O.

Biochim Biophys Acta. 2015 Feb 7. pii: S0304-4165(15)00044-6. doi: 10.1016/j.bbagen.2015.01.022. [Epub ahead of print] Review.

PMID:
25662818
9.

Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b.

Ingwersen J, Menge T, Wingerath B, Kaya D, Graf J, Prozorovski T, Keller A, Backes C, Beier M, Scheffler M, Dehmel T, Kieseier BC, Hartung HP, Küry P, Aktas O.

Ann Clin Transl Neurol. 2015 Jan;2(1):43-55. doi: 10.1002/acn3.152. Epub 2014 Dec 5.

10.

Axonal damage in papilledema linked to idiopathic intracranial hypertension as revealed by multifocal visual evoked potentials.

Hartmann CJ, Klistorner AI, Brandt AU, Schroeder K, Kolbe R, Cohn E, Goebels N, Guthoff R, Aktas O, Hartung HP, Albrecht P.

Clin Neurophysiol. 2014 Dec 27. pii: S1388-2457(14)00858-X. doi: 10.1016/j.clinph.2014.12.014. [Epub ahead of print] No abstract available.

PMID:
25613033
11.

Oligodendroglial maturation is dependent on intracellular protein shuttling.

Göttle P, Sabo JK, Heinen A, Venables G, Torres K, Tzekova N, Parras CM, Kremer D, Hartung HP, Cate HS, Küry P.

J Neurosci. 2015 Jan 21;35(3):906-19. doi: 10.1523/JNEUROSCI.1423-14.2015.

12.

Subtle retinal pathology in amyotrophic lateral sclerosis.

Ringelstein M, Albrecht P, Südmeyer M, Harmel J, Müller AK, Keser N, Finis D, Ferrea S, Guthoff R, Schnitzler A, Hartung HP, Methner A, Aktas O.

Ann Clin Transl Neurol. 2014 Apr;1(4):290-7. doi: 10.1002/acn3.46. Epub 2014 Mar 11.

13.

Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab.

Harmel J, Ringelstein M, Ingwersen J, Mathys C, Goebels N, Hartung HP, Jarius S, Aktas O.

BMC Neurol. 2014 Dec 17;14(1):247. doi: 10.1186/s12883-014-0247-3.

14.

Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Miller-Little WA, Stuve O.

Expert Rev Clin Immunol. 2015 Jan;11(1):93-108. doi: 10.1586/1744666X.2015.992881. Epub 2014 Dec 15.

PMID:
25495182
15.

The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.

Kremer D, Förster M, Schichel T, Göttle P, Hartung HP, Perron H, Küry P.

Mult Scler. 2014 Dec 5. pii: 1352458514560926. [Epub ahead of print]

PMID:
25480862
16.

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.

Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kümpfel T, Hohlfeld R, Mäurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, Wattjes MP, Svenningsson A, Olsson T, Hartung HP, Hermsen D, Tumani H, Adams O, Kieseier BC.

Mult Scler. 2014 Nov 12. pii: 1352458514556296. [Epub ahead of print]

PMID:
25392339
17.

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Pasquier RD, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH.

Mult Scler. 2014 Nov 12. pii: 1352458514554052. [Epub ahead of print]

PMID:
25392325
18.

Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.

Kaufman M, Cree BA, De Sèze J, Fox RJ, Gold R, Hartung HP, Jeffery D, Kappos L, Montalbán X, Weinstock-Guttman B, Ticho B, Duda P, Pace A, Campagnolo D.

J Neurol. 2015 Feb;262(2):326-36. doi: 10.1007/s00415-014-7558-6. Epub 2014 Nov 9.

PMID:
25381458
19.

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.

Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung HP, Olsson T, Kieseier BC.

Neurology. 2014 Dec 2;83(23):2153-7. doi: 10.1212/WNL.0000000000001049. Epub 2014 Oct 31.

PMID:
25361781
20.

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.

Hartung HP, Aktas O, Boyko AN.

Mult Scler. 2015 Jan;21(1):22-34. doi: 10.1177/1352458514549398. Epub 2014 Oct 24. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk